(Q42790616)

English

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

scientific article published on November 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 November 2017

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections (English)

1 reference

Europe PubMed Central

7 November 2017

0 references

ceftaroline fosamil

1 reference

ChEBI release 2020-05-28

2

object named as

Mark H Wilcox

0 references

author name string

G Ralph Corey

1

1 reference

Europe PubMed Central

7 November 2017

George H Talbot

3

1 reference

Europe PubMed Central

7 November 2017

Dirk Thye

4

1 reference

Europe PubMed Central

7 November 2017

David Friedland

5

1 reference

Europe PubMed Central

7 November 2017

Tanya Baculik

6

1 reference

Europe PubMed Central

7 November 2017

CANVAS 1 investigators

7

1 reference

Europe PubMed Central

7 November 2017

language of work or name

0 references

publication date

1 November 2010

1 reference

Europe PubMed Central

7 November 2017

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

7 November 2017

65 Suppl 4

1 reference

Europe PubMed Central

7 November 2017

iv41-51

1 reference

Europe PubMed Central

7 November 2017

Waves of resistance: Staphylococcus aureus in the antibiotic era.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

Methicillin-resistant Staphylococcus aureus, Western Australia

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in Latin America

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains?

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

Invasive methicillin-resistant Staphylococcus aureus infections in the United States

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ254

21 January 2018

Identifiers

10.1093/JAC/DKQ254

1 reference

Europe PubMed Central

7 November 2017

1 reference

Europe PubMed Central

7 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42790616&oldid=2164315903"